COVIDH TECHNOLOGIES LIMITED

Covidh Technologies Limited announced its name change to iSERA Lifesciences Limited, effective June 16, 2026. The company's scrip ID on BSE will also change from 'COVIDH' to 'ISERA'. This rebranding aligns with the company's strategic shift towards the life sciences, pharmaceutical, biotechnology, and allied healthcare sectors. The Board also approved a new corporate logo reflecting this new identity. The company addressed a prior non-compliance with SEBI LODR Regulations regarding the name change application and has taken corrective steps, including shareholder ratification at an upcoming general meeting. Management has been directed to ensure future regulatory compliance.

Covidh Technologies Ltd, now known as iSERA Lifesciences Limited, declares that Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is not applicable to the company. As of March 31, 2026, the company's paid-up equity share capital and net worth are less than ₹10 Crore and ₹25 Crore respectively, meeting the exemption criteria under Regulation 15(2) of SEBI (LODR) Regulations, 2015.

Covidh Technologies Ltd, now known as iSERA Lifesciences Limited, has submitted its audited financial results for the year ended March 31, 2026, as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Board of Directors approved the results at a meeting held on May 21, 2026, which included the standalone financial results and the independent auditor's report with an unmodified opinion.

iSERA Lifesciences Limited (formerly Covidh Technologies Limited) announced the approval of its audited financial results for the year ended March 31, 2026, during a board meeting held on May 21, 2026. The board also approved the Independent Auditor’s Report and a declaration for unmodified opinion on the financial results.

iSERA Lifesciences Limited (formerly Covidh Technologies Limited) has announced the approval of its audited financial results (standalone) for the quarter and year ended March 31, 2026. The decision was made during a Board of Directors meeting held on May 21, 2026, which commenced at 07:00 P.M. and concluded at 07:40 P.M. The board also approved the Independent Auditor’s Report and a declaration for unmodified opinion regarding the audited standalone financial results.

iSERA Lifesciences Limited (formerly Covidh Technologies Limited) has filed a monitoring agency report for the quarter ended March 31, 2026, regarding the utilization of proceeds from its Rights Issue. The report, issued by Infomerics Valuation and Rating Private Limited, details the status of the utilization of issue proceeds as per Regulation 82 of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 and Regulation 32(6) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The report indicates no deviation from the stated objectives.

iSERA Lifesciences Limited (formerly Covidh Technologies Limited) submits a Monitoring Agency Report by Infomerics Valuation and Rating Private Limited regarding the utilization of proceeds from its Rights Issue for the quarter ended March 31, 2026. The report indicates no deviation from the stated objectives of the issue. The monitoring agency declares no conflict of interest and confirms the report provides a true and fair view of the utilization of issue proceeds, based on information provided by the issuer and other reliable sources.

Covidh Technologies Ltd has scheduled a Board of Directors meeting on May 21, 2026, to consider and approve the Audited Financial Results for the quarter and year ended March 31, 2026. In compliance with SEBI regulations, the trading window for the company's equity shares will be closed for designated persons from April 1, 2026, until 48 hours after the results are made public. The notice is available on the company's and BSE's websites.

iSERA Lifesciences Limited (formerly Covidh Technologies Limited) announced the revised outcome of its Board Meeting held on April 21, 2026. The Board approved increasing the Authorised Share Capital from ₹11 Crore to ₹25 Crore, subject to shareholder approval. Additionally, the Board approved the adoption of new Memorandum and Articles of Association to align with the Companies Act, 2013, also subject to shareholder approval via special resolution. The limit for investments, loans, or guarantees under Section 186 of the Companies Act, 2013, was enhanced to ₹1,000 Crore, pending shareholder approval. The Board also took on record and approved valuation reports for a proposed preferential issue of equity shares on a Share Swap basis.

The Board of Directors of iSERA Lifesciences Limited (formerly Covidh Technologies Ltd) met on April 21, 2026, and approved several key matters. The authorized share capital was increased from ₹11 Crore to ₹25 Crore. The Board also approved the adoption of new Memorandum and Articles of Association to align with the Companies Act, 2013. Additionally, limits for investments, loans, or guarantees under Section 186 of the Companies Act, 2013 were enhanced to ₹1,000 Crore. Crucially, the Board approved valuation reports and the swap ratio for a proposed preferential issue of equity shares on a share swap basis, with iSERA Lifesciences' shares valued at ₹48.15. All these approvals are subject to shareholder approval via postal ballot/e-voting.